Collegium Pharmaceutical Stock News

STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second q

Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.

Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.

Shares of pain management drug concern Collegium Pharmaceutical have fallen over 40% as the biotech selloff, negative attitudes towards opiates, and patent cliffs have taken a toll. The company's rece

Some very small stocks, micro-cap stocks, have good value and are overlooked and should be considered by investors to buy today. The post 7 Micro-Cap Stocks to Take a Chance on Now appeared first on I

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Alex Dasalla - Head of IR & Corporate Communications Joe Ciaffoni - Presiden

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host

A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.

The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.

INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.

Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.